Influence of Intermittent Hypoxia on Loop Gain in Healthy Subjects

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-45
SponsorPoitiers University Hospital

About this trial

Sleep apnoea-hypopnoea syndrome (SAHOS), which causes numerous comorbidities, particularly cardiovascular ones, is widespread worldwide today and incurs significant healthcare costs.

Current research in this field focuses on identifying different phenotypes in affected patients in order to provide more personalised treatment.

One of these phenotypes appears to be linked to instability in ventilatory control due to an increase in loop gain (LG) in these subjects.

However, the pathophysiology of this ventilatory control instability due to increased LG is not fully understood. It is still difficult to determine whether subjects have an intrinsically high LG or if exposure to intermittent hypoxia during OSA promotes an increase in LG.

It has also been demonstrated that OSA causes vascular hyperreactivity by increasing oxidative stress through elevated ROS production. This leads to endothelial dysfunction in response to intermittent hypoxia associated with apnoea. Extracellular vesicles (microvesicles and exosomes) have been shown to play a role in this endothelial response. These extracellular vesicles are essential for intercellular communication in both physiological and pathological situations, such as SAHOS.

Therefore, the objective of this research is to determine whether exposure to intermittent hypoxia and changes in microvesicle phenotype could influence LG, which could lead to new therapeutic advances in the context of SAHOS.

Eligibility criteria

Qualifiers

Healthy subjects aged 18 to 45

BMI between [18-25] kg/m2

No known sleep disorders

Free subjects, not under guardianship or curatorship or subordination

Disqualifiers

Active smoking or cessation within the last 3 months and total consumption > 10 pack-years

Alcohol or drug addiction

Excessive coffee consumption (> 3 espressos/day)

History of acute mountain sickness (presence of symptoms such as dizziness, headaches, nausea/vomiting, and incapacitating fatigue during or after a stay at high altitude)

Trial design

Treatments tested in this trial

  • Intermittent hypoxia
  • Normoxia

Treatment groups

40 Participants
are divided into 2 treatment groups

Sponsors and collaborators